The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner.
Joseph MazarJeanne K BrooksMatthew PeloquinRosa RosarioEmma SuttonMatthew LongoDennis DrehnerTamarah J WestmorelandPublished in: Cancer research communications (2024)
Sensitivity to the tumoricidal effect of ZIKV on high-risk neuroblastoma tumors is dependent on CD24 expression, offering a prognostic marker for this oncolytic therapy in an extensive array of CD24-expressing cancers.